AX-2026-041213
NAD+ · 500 mg declared · Wuhan Wansheng Biotechnology Co., Ltd. · lot WWB-2601-V1583
- Report ID
- AX-2026-041213
- Compound
- NAD+
- Compound class
- Non-peptide adjuncts
- Supplier
- WWB — Wuhan Wansheng Biotechnology Co., Ltd.
- Batch / lot
- WWB-2601-V1583
- Declared label claim
- 500mg
- Laboratory
- VendorInvestigate
- Assay date
- 12 May 2026
- Submitted
- 16 May 2026
- Quarter
- 2026-Q2
- Submitter
- two_labs_one_lot
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the non-peptide adjuncts class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 32 min gradient, 214 nm | 99.04 | % area | ≥ 97.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.96 | % area | ≤ 3.0 | PASS |
| Largest single impurity | RP-HPLC — NADH (reduced, +2 Da) | 0.62 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 663.1091 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 663.1098 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | +1.0 | ppm | ± 10 | PASS |
| Peptide content | not ordered on this submission | not determined | — | required to check label claim | NOT TESTED |
| Water content | Karl Fischer, coulometric, duplicate | 11.41 | % | ≤ 10.0 | FAIL |
| Counter-ion | no ionisable counter-ion expected | N/A | — | not applicable | NOT TESTED |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.51 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White powder, no defined cake (melt-back) | — | white to off-white intact cake | FAIL |
| Reconstitution clarity | reconstituted per submitter procedure | Faint haze, clearing on standing | — | clear, no visible particulates | FAIL |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 6.47 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 32 min gradient | 4.51 | min | 4.42 ± 0.25 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 0.97 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 73,538 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs α-NAD anomer | 2.82 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | NAD+ — main peak | 4.51 | 4,813,651 | 99.04 | — |
| 2 | NADH (reduced, +2 Da) | 4.87 | 30,134 | 0.62 | +2.016 |
| 3 | nicotinamide (−541 Da) | 3.78 | 10,693 | 0.22 | -541.052 |
| 4 | α-NAD anomer | 4.70 | 3,888 | 0.08 | 0.000 |
| 5 | nicotinamide mononucleotide (NMN, −331 Da) | 4.06 | 1,458 | 0.03 | -331.058 |
| 6 | ADP-ribose (−121 Da) | 4.23 | 486 | 0.01 | -121.040 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 663.1091 Da, computed from C21H27N7O14P2. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 2+ | 332.5618 | 332.5622 | 0.0004 | 56.9 |
| 1+ | 664.1164 | 664.1171 | 0.0007 | 100.0 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.90 | 99.04 | divergence +0.27 pp vs batch median |
| Total impurities (% area) | 0.10 | 0.96 | |
| Largest single impurity (% area) | 0.06 | 0.62 | |
| Water (%) | not stated | 11.41 | |
| Counter-ion (%) | 5.9 | N/A | |
| Peptide content (%w/w) | 90.0 | not determined | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Domestic warehouse despatch → submitter (2–8 °C, 19 d) → laboratory (courier, cold pack, 12 d) → assay.
- Assay date
- 12 May 2026
- Submitted to the index
- 16 May 2026
- Laboratory
- VendorInvestigate, Riga, Latvia
- Method basis
- 32 min gradient · high-resolution MS
- Verification status
- PARTIAL
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot WWB-2601-V1583 n=6
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041208 | WWB-2601-V1583 | VendorInvestigate | 2026-Q2 | 99.18 | 11.38 | 100.9 | Buyer-sourced | 0 | FAIL |
| AX-2026-041209 | WWB-2601-V1583 | Nordanalyt | 2026-Q2 | 99.82 | 11.64 | — | Supplier-supplied | 0 | FAIL |
| AX-2026-041210 | WWB-2601-V1583 | Nordanalyt | 2026-Q2 | 99.43 | 11.19 | 95.3 | Supplier-supplied | 0 | FAIL |
| AX-2026-041211 | WWB-2601-V1583 | Janoshik | 2026-Q2 | 99.93 | 11.52 | 92.9 | Supplier-supplied | 0 | FAIL |
| AX-2026-041212 | WWB-2601-V1583 | Janoshik | 2026-Q2 | 99.93 | 10.36 | 88.5 | Laboratory-retained | 1 | FAIL |
Cross-sections
- All NAD+ records n=48
- All WWB records n=522
- All VendorInvestigate records n=601
- All 2026-Q2 records n=1009
- NAD+ by supplier
- NAD+ impurity profile
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041208 | WWB | WWB-2601-V1583 | VendorInvestigate | 2026-Q2 | 99.18 | 11.38 | 100.9 | Buyer-sourced | 0 | FAIL |
| AX-2026-041209 | WWB | WWB-2601-V1583 | Nordanalyt | 2026-Q2 | 99.82 | 11.64 | — | Supplier-supplied | 0 | FAIL |
| AX-2026-041210 | WWB | WWB-2601-V1583 | Nordanalyt | 2026-Q2 | 99.43 | 11.19 | 95.3 | Supplier-supplied | 0 | FAIL |
| AX-2026-042457 | SWB | SWB-2602-P5992 | PeptideMeter | 2026-Q2 | 99.06 | 10.72 | 96.8 | Supplier-supplied | 1 | FAIL |
| AX-2026-041211 | WWB | WWB-2601-V1583 | Janoshik | 2026-Q2 | 99.93 | 11.52 | 92.9 | Supplier-supplied | 0 | FAIL |
| AX-2026-042456 | SWB | SWB-2602-P5992 | Medutest | 2026-Q2 | 98.89 | 10.27 | 101.6 | Supplier-supplied | 2 | FAIL |
| AX-2026-042454 | SWB | SWB-2602-P5992 | Janoshik | 2026-Q2 | 98.64 | 11.21 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-042455 | SWB | SWB-2602-P5992 | Janoshik | 2026-Q2 | 99.22 | 10.60 | — | Supplier-supplied | 1 | FAIL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041275 | Liraglutide | WWB-2607-X2189 | Nordanalyt | 2026-Q3 | 99.61 | 5.03 | 97.3 | Supplier-supplied | 0 | PASS |
| AX-2026-041387 | BPC-157 | WWB-2606-H3906 | Janoshik | 2026-Q3 | 98.95 | 4.64 | — | Laboratory-retained | 1 | MARGINAL |
| AX-2026-041334 | Semaglutide | WWB-2606-N3192 | Janoshik | 2026-Q3 | 98.83 | 5.04 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041337 | Semaglutide | WWB-2606-N3192 | Nordanalyt | 2026-Q3 | 98.96 | 4.81 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041385 | BPC-157 | WWB-2606-H3906 | Medutest | 2026-Q3 | 99.31 | 4.31 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041390 | BPC-157 | WWB-2606-H3906 | Medutest | 2026-Q3 | 99.47 | 4.84 | 99.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041386 | BPC-157 | WWB-2606-H3906 | VendorInvestigate | 2026-Q3 | 99.32 | 4.88 | 99.2 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041335 | Semaglutide | WWB-2606-N3192 | Janoshik | 2026-Q3 | 99.55 | 4.55 | 100.5 | Supplier-supplied | 1 | MARGINAL |